Twist Bioscience (TWST) Advances +15% Over 30 Days on AI Collaboration Momentum
Key Takeaways
- Twist Bioscience (TWST) rose roughly 15% over the trailing 30 days, climbing from about $145 in late August to $166.99 at the September 18 close.
- The rally accelerated after Twist announced a data-services agreement with Eli Lilly's (LLY) AI-driven TuneLab platform, sending shares up more than 31% in a single week.
- Over the trailing three months, the stock has gained roughly 90%, reflecting growing investor enthusiasm for AI-enabled drug discovery and synthetic biology demand.
- Key catalysts include fiscal 2026 revenue-guidance raises, an Anthropic partnership, a $300 million follow-on offering, and analyst price-target increases.
- Twist remains loss-making with a premium valuation, leaving the stock sensitive to execution and shifts in AI-demand sentiment.
Company Background and Market Position
Twist Bioscience Corporation operates in synthetic biology and genomics, producing synthetic DNA on a proprietary silicon-chip platform. It has expanded into synthetic genes, next-generation sequencing tools, sample preparation, antibody libraries, and biologic discovery services, serving pharmaceutical firms, biotech companies, academic institutions, and industrial clients.
Under co-founder and CEO Emily Leproust, the business is increasingly viewed as a key supplier to the AI drug discovery space. Its wet-lab services for antibody characterization and DNA synthesis support machine-learning models. I follow TWST for its exposure here, along with its consistent double-digit revenue growth and progress toward profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance Over the Past 30 Days and Quarter
Over the last 30 days, TWST moved from a closing price of $145.59 on August 21 to $166.99 on September 18, for a gain of approximately 14.7%. The path was uneven, with consolidation in the low-to-mid $120s to low $140s for much of the period before a sharp mid-September breakout.
The quarterly picture looks even stronger. From a mid-June close of $87.56, the stock advanced roughly 90% over three months. Over the past year it has more than quadrupled, and year-to-date gains exceed 300%, pointing to a sustained re-rating tied to the AI drug discovery story rather than a brief spike.
Drivers Behind the Recent 30-Day Move
The main catalyst arrived on September 16 when Twist joined Lilly TuneLab, Eli Lilly’s AI/ML drug discovery platform. Twist will supply antibody characterization data services to feed Lilly’s models, generating revenue while also gaining access to collaborative research findings. The two-way arrangement lifted the stock about 14% on the news and more than 31% for the week.
Analyst notes added support. Leerink Partners lifted its price target to $160 from $120 while keeping an Outperform rating, and UBS started coverage with a Neutral rating and $144 target. BWS Financial took a more cautious stance, reiterating a Sell rating and $45 target on the view that the Lilly deal offers limited strategic upside.
Earlier groundwork included the August 3 report of fiscal third-quarter 2026 revenue at $118.4 million, up more than 23% year over year, plus a raised full-year guidance range of $456 million–$457 million. An upsized $300 million follow-on offering at $96 per share closed in early August. A CEO insider-sale filing for up to 295,037 shares stood out against the bullish backdrop.
Quarterly Momentum and Longer-Term Catalysts
The roughly 90% three-month advance reflects a broader shift in how investors see Twist, moving from a traditional life-science tools provider toward an AI-levered platform. In August the company was named an independent experimental service provider for Anthropic, handling wet-lab work on AI-designed mini-binder proteins. Combined with the later Lilly TuneLab agreement, these steps positioned Twist as a beneficiary of rising demand for wet-lab validation in AI drug discovery.
On the fundamentals, Twist has now posted fourteen straight quarters of sequential revenue growth with gross margins above 52%. Management has guided to adjusted EBITDA breakeven in the fourth quarter of fiscal 2026 and expects AI-related drug discovery orders to scale from roughly $25 million in 2025 to $100 million in 2027, supporting a longer-term goal of doubling revenue by fiscal 2031.
Key Factors Investors Should Watch Next
Attention will focus on fourth-quarter fiscal 2026 results, where guidance points to revenue of roughly $123 million–$124 million, or about 25% year-over-year growth, alongside the adjusted EBITDA breakeven target. The fiscal 2027 order outlook will also matter as the market looks for signs that AI collaborations convert into booked, recurring revenue.
Other items include the undisclosed value and duration of the Lilly TuneLab agreement, the path of AI drug discovery order volumes, and competitive moves from peers such as DNA (Ginkgo Bioworks). Valuation stays a key risk, with a price-to-sales ratio above 20x and the company still unprofitable; any slowdown in AI demand or execution shortfall could pressure sentiment, as could additional equity offerings.
Integrating AI Tools Into My Research Process
When evaluating names like TWST, I sometimes turn to Tickeron’s AI Daily Buy/Sell Signals to cross-check momentum against broader market patterns. The platform’s data-driven signals help me quickly gauge whether recent moves align with historical precedents or stand out as outliers, adding a useful quantitative layer to the fundamental story without replacing deeper analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
TWST's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for TWST turned positive on September 17, 2026. Looking at past instances where TWST's MACD turned positive, the stock continued to rise in 42 of 45 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 16, 2026. You may want to consider a long position or call options on TWST as a result. In 69 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
Following a +16.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where TWST advanced for three days, in 234 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 184 of 232 cases where TWST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TWST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TWST broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TWST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 66 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (24.814) is normal, around the industry mean (25.929). P/E Ratio (0.000) is within average values for comparable stocks, (40.079). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.178). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (437.043).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of proprietary semiconductor-based synthetic DNA manufacturing process
Industry Biotechnology
Advertisement